KDR and neoplasm: Similarly to sunitinib, cabozantinib inhibits the tyrosine kinase enzymatic activities of multiple receptors including VEGFR2, MET, AXL, and RET, which have been implicated in tumor proliferation, survival and neoangiogenesis [14, 24, 25].